| 20.97 0.4 (1.94%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.99 |
1-year : | 30.65 |
| Resists | First : | 23.96 |
Second : | 26.25 |
| Pivot price | 21.68 |
|||
| Supports | First : | 20.27 | Second : | 16.86 |
| MAs | MA(5) : | 21.63 |
MA(20) : | 22.35 |
| MA(100) : | 22.8 |
MA(250) : | 30.9 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 28 |
| RSI | RSI(14): 41.4  |
|||
| 52-week | High : | 48.11 | Low : | 13.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GPCR ] has closed above bottom band by 21.5%. Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 21.11 - 21.24 | 21.24 - 21.36 |
| Low: | 20.17 - 20.32 | 20.32 - 20.46 |
| Close: | 20.74 - 20.96 | 20.96 - 21.17 |
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Tue, 10 Jun 2025
Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous (GPCR) - Seeking Alpha
Thu, 29 May 2025
Structure Therapeutics Set for Jefferies and Goldman Sachs Healthcare Conference Presentations in June - Stock Titan
Fri, 25 Apr 2025
Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts? - Yahoo Finance
Thu, 17 Apr 2025
Structure Therapeutics (GPCR) Gains on Eli Lilly's Diabetes Drug Data Release - GuruFocus
Tue, 15 Apr 2025
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 58 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 101.1 (%) |
| Shares Short | 9,320 (K) |
| Shares Short P.Month | 7,020 (K) |
| EPS | -2.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.3 % |
| Return on Equity (ttm) | -22.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -135 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -8.13 |
| PEG Ratio | 0 |
| Price to Book value | 1.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|